Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013003434> ?p ?o ?g. }
- W2013003434 endingPage "1202" @default.
- W2013003434 startingPage "1195" @default.
- W2013003434 abstract "The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore representing a major target for drug development in this disease. We show here that the specific mTOR kinase inhibitor AZD8055 blocked mTORC1 and mTORC2 signaling in AML. Particularly, AZD8055 fully inhibited multisite eIF4E-binding protein 1 phosphorylation, subsequently blocking protein translation, which was in contrast to the effects of rapamycin. In addition, the mTORC1-dependent PI3K/Akt feedback activation was fully abrogated in AZD8055-treated AML cells. Significantly, AZD8055 decreased AML blast cell proliferation and cell cycle progression, reduced the clonogenic growth of leukemic progenitors and induced caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. Interestingly, AZD8055 strongly induced autophagy, which may be either protective or cell death inducing, depending on concentration. Finally, AZD8055 markedly increased the survival of AML transplanted mice through a significant reduction of tumor growth, without apparent toxicity. Our current results strongly suggest that AZD8055 should be tested in AML patients in clinical trials." @default.
- W2013003434 created "2016-06-24" @default.
- W2013003434 creator A5004158420 @default.
- W2013003434 creator A5007247346 @default.
- W2013003434 creator A5013426510 @default.
- W2013003434 creator A5016016794 @default.
- W2013003434 creator A5024027732 @default.
- W2013003434 creator A5026525163 @default.
- W2013003434 creator A5029880064 @default.
- W2013003434 creator A5031776733 @default.
- W2013003434 creator A5032299990 @default.
- W2013003434 creator A5034278655 @default.
- W2013003434 creator A5038903944 @default.
- W2013003434 creator A5039959145 @default.
- W2013003434 creator A5040373927 @default.
- W2013003434 creator A5046325152 @default.
- W2013003434 creator A5053199721 @default.
- W2013003434 creator A5061163564 @default.
- W2013003434 creator A5069894834 @default.
- W2013003434 creator A5072928493 @default.
- W2013003434 creator A5073487686 @default.
- W2013003434 creator A5074862578 @default.
- W2013003434 creator A5088509972 @default.
- W2013003434 date "2011-12-06" @default.
- W2013003434 modified "2023-10-18" @default.
- W2013003434 title "The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia" @default.
- W2013003434 cites W1964675052 @default.
- W2013003434 cites W1965626427 @default.
- W2013003434 cites W1970550717 @default.
- W2013003434 cites W1970707895 @default.
- W2013003434 cites W1974964167 @default.
- W2013003434 cites W1976643149 @default.
- W2013003434 cites W1992170852 @default.
- W2013003434 cites W1994186909 @default.
- W2013003434 cites W1996092483 @default.
- W2013003434 cites W2009303397 @default.
- W2013003434 cites W2009886463 @default.
- W2013003434 cites W2011876955 @default.
- W2013003434 cites W2025391287 @default.
- W2013003434 cites W2029787353 @default.
- W2013003434 cites W2032788851 @default.
- W2013003434 cites W2035521247 @default.
- W2013003434 cites W2041399083 @default.
- W2013003434 cites W2060157525 @default.
- W2013003434 cites W2062646606 @default.
- W2013003434 cites W2065887259 @default.
- W2013003434 cites W2068661213 @default.
- W2013003434 cites W2080100938 @default.
- W2013003434 cites W2087598047 @default.
- W2013003434 cites W2089313118 @default.
- W2013003434 cites W2089716875 @default.
- W2013003434 cites W2094817491 @default.
- W2013003434 cites W2098912234 @default.
- W2013003434 cites W2109387038 @default.
- W2013003434 cites W2112519486 @default.
- W2013003434 cites W2113343850 @default.
- W2013003434 cites W2115655607 @default.
- W2013003434 cites W2121190158 @default.
- W2013003434 cites W2134234801 @default.
- W2013003434 cites W2134719928 @default.
- W2013003434 cites W2140737563 @default.
- W2013003434 cites W2146788325 @default.
- W2013003434 cites W2152289580 @default.
- W2013003434 cites W2154836325 @default.
- W2013003434 cites W2156320420 @default.
- W2013003434 cites W2157882510 @default.
- W2013003434 cites W2159714906 @default.
- W2013003434 cites W2163382569 @default.
- W2013003434 cites W4238567307 @default.
- W2013003434 doi "https://doi.org/10.1038/leu.2011.339" @default.
- W2013003434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22143671" @default.
- W2013003434 hasPublicationYear "2011" @default.
- W2013003434 type Work @default.
- W2013003434 sameAs 2013003434 @default.
- W2013003434 citedByCount "137" @default.
- W2013003434 countsByYear W20130034342012 @default.
- W2013003434 countsByYear W20130034342013 @default.
- W2013003434 countsByYear W20130034342014 @default.
- W2013003434 countsByYear W20130034342015 @default.
- W2013003434 countsByYear W20130034342016 @default.
- W2013003434 countsByYear W20130034342017 @default.
- W2013003434 countsByYear W20130034342018 @default.
- W2013003434 countsByYear W20130034342019 @default.
- W2013003434 countsByYear W20130034342020 @default.
- W2013003434 countsByYear W20130034342021 @default.
- W2013003434 countsByYear W20130034342022 @default.
- W2013003434 countsByYear W20130034342023 @default.
- W2013003434 crossrefType "journal-article" @default.
- W2013003434 hasAuthorship W2013003434A5004158420 @default.
- W2013003434 hasAuthorship W2013003434A5007247346 @default.
- W2013003434 hasAuthorship W2013003434A5013426510 @default.
- W2013003434 hasAuthorship W2013003434A5016016794 @default.
- W2013003434 hasAuthorship W2013003434A5024027732 @default.
- W2013003434 hasAuthorship W2013003434A5026525163 @default.
- W2013003434 hasAuthorship W2013003434A5029880064 @default.
- W2013003434 hasAuthorship W2013003434A5031776733 @default.
- W2013003434 hasAuthorship W2013003434A5032299990 @default.
- W2013003434 hasAuthorship W2013003434A5034278655 @default.